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INTRODUCTION
Clostridium difficile
Continuing with the tradition we adopted last August, I am
pleased to present readers with a special theme issue on Clos-
tridium difficile. Today, C. difficile is the causal agent of a large
number of cases of nosocomially acquired diarrhea, particularly
those that occur after administration of antimicrobial drugs, and
following almost all episodes of colitis with pseudomembranes
on the mucosa of the colon wall. This curious organism, whose
growth in the laboratory is not as ‘difficult’ as its name leads us to
believe, can produce toxins (A and B), to which we attribute its
most evident pathogenic properties. Alongside the classic
strains, we can also identify variants capable of producing only
one of the toxins we have come to know better over recent
years.
Besides being a frequent cause of nosocomial infection,
C. difficile probably plays a more important role than previously
thought in community-acquired diarrhea, particularly in
patients treated with antibiotics. The easy transmission of
infection in hospitals and the appearance and development of
highly epidemic outbreaks justify the attention paid, not only to
the disease itself, but also to the characterisation and typing of
C. difficile, to measures ensuring rapid diagnosis, and to the
procedures designed to control the disease.
Treatment, in addition to suspending the administration of
antibiotics when possible, requires the administration of new
antimicrobial drugs, specifically metronidazole or vancomycin.
Today, metronidazole is widely considered the drug of choice
for the treatment of C. difficile-associated diarrhea (CDAD),
given its effective in vitro activity against the organism, its
efficacy when administered orally or parenterally, its low capa-
city for selecting microorganisms with a high potential for
nosocomial spread, and its low cost. Vancomycin, on the other
hand, is considered by many to be a second-choice agent,
mainly because of its capacity for selecting vancomycin resis-
tant enterococci (VRE), its efficacy limited to topical admin-
istration (oral or in enemas) and its higher price, all of which
reserve it for metronidazole failures. Both drugs are associated
with an undesirable number of recurrences that require the
administration of new and longer cycles of antimicrobial drugs
and the coadministration of agents such as Saccharomyces bou-
lardii.
Until now, most microbiology laboratories have not thought
it necessary to carry out routine susceptibility tests for C. difficile
isolates against both drugs, as their activity was considered
universal and predictable. This situation may change; resistance
to metronidazole in C. difficile has already been described in
some strains and there are isolates with ‘intermediate’ suscept-
ibility to vancomycin. We are thus faced with a pathogen which
occurs following antibiotic therapy, but which, paradoxically,
requires more antibiotics for its eradication, and which, unfor-
tunately, can lead to new resistance.
Given this state of affairs, it is natural that many members of
the European Society of Clinical Microbiology and Infectious
Diseases have requested the formation of a C. difficile study
group, which held its first symposium at the recent ECCMID in
Istanbul. We feel that it was a good idea to invite the President of
the group and moderator of the session, Jon Brazier, and the
colleagues who accompanied him, to present papers to CMI
and to bring these together in this issue. These papers discuss the
epidemiology of CDAD, its pathogenicity, the best methods for
laboratory diagnosis, the detection of variant strains, typing
systems and a model for approaching the complex dynamics
leading to the spread of this infection. We thought it suitable to
also include several original articles on the same subject that had
been submitted spontaneously and that offer a complementary
view of the problem from a mainly European perspective.
If our readers are pleased with this collection of papers, if this
issue helps them in their daily work, if it stimulates them in their
research or helps them to better manage C. difficile-associated
problems, all of those who have worked on this issue will be well
rewarded.
Finally, I would like to invite other groups involved with a
subject they consider of interest to our readers to contact the
Editorial office to discuss the possibility of a future special theme
issue.
Prof. Emilio Bouza
Editor-in-Chief
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